Study on CYP2D8P: Key Player in Drug Metabolism (G1568)

Target Name: CYP2D8P

NCBI ID: G1568

CYP2D8P

Other Name(s): CYP2DP1 | ccytochrome P450 family 2 subfamily D member 8, pseudogene | CYP2D8P1 | Cytochrome P450 family 2 subfamily D member 8, pseudogene

Study on CYP2D8P: Key Player in Drug Metabolism

CYP2D8P (CYP2DP1) is a gene that encodes for a protein known as the CYP2D8 enzyme. This enzyme is a key player in the metabolism of many drugs, including many statins, benzodiazepines, and opioids. As a result, CYP2D8P has become a drug target of great interest in recent years, with a number of research studies investigating its role in drug metabolism and its potential as a biomarker for drug response.

The CYP2D8 enzyme is a member of the cytochrome P450 (CYP) family, which is responsible for a wide range of cellular processes, including drug metabolism and metabolism of endogenous compounds. The CYP2D8 enzyme is primarily located in the liver and other tissues, and is responsible for the metabolism of many different drugs, including many statins, benzodiazepines, and opioids.

CYP2D8P is encoded by the DNA gene and is located on chromosome 11. It consists of 184 amino acid residues and has a calculated pI of 9.95. The CYP2D8 enzyme is highly conserved, with only a single known substrate, 2-fluorothiargen (2-Ft), and a limited number of known inhibitors.

One of the key challenges in studying CYP2D8P is its high degree of genetic and phenotypic variability. Because it is a gene that is expressed in many different tissues and cells, it is difficult to study its function in isolation. Additionally, the CYP2D8 enzyme is involved in the metabolism of many different drugs, which can affect its function and the outcome of drug studies.

To study the role of CYP2D8P in drug metabolism, researchers have used a variety of techniques, including genetic modulation, RNA interference, and mass spectrometry. These techniques have allowed researchers to identify the key role of CYP2D8P in drug metabolism and to understand its underlying mechanisms.

One of the most significant findings of recent studies on CYP2D8P was the identification of a genetic region that is associated with the metabolism of many statins. This region includes the amino acids Asp112, Asn113, Asp114, and Asp115, which are located at positions 112, 113, 114, and 115 in the CYP2D8 protein sequence.

In addition to its role in drug metabolism, CYP2D8P is also of interest as a potential biomarker for drug response. Because it is involved in the metabolism of many different drugs, including many statins, researchers have used CYP2D8P as a biomarker to assess the effectiveness of different statins in clinical trials.

One of the challenges of using CYP2D8P as a biomarker for drug response is the difficulty in predicting the metabolism of a particular drug by this enzyme. This is because the metabolism of a drug by CYP2D8P can be influenced by many different factors, including the dose and timing of drug administration, as well as genetic and phenotypic differences in the liver.

To address this challenge, researchers have developed models to predict the metabolism of a drug by CYP2D8P based on its chemical structure and other properties. These models can be used to identify potential drug candidates that are likely to be metabolized by CYP2D8P and to assess the effectiveness of different drugs in clinical trials.

Overall, CYP2D8P is a gene that has significant implications for drug metabolism and response. Its role in the metabolism of many different drugs makes it an attractive target for

Protein Name: Ccytochrome P450 Family 2 Subfamily D Member 8, Pseudogene

The "CYP2D8P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2D8P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets